Positron Emission Tomography Market - Global Forecast 2025-2032

As the landscape of medical diagnostics evolves, the Positron Emission Tomography (PET) market stands out for its transformative impact on clinical pathways, empowering providers with deeper molecular insights and operational efficiency. Senior decision-makers are increasingly recognizing the modality's central role in advancing precision medicine and optimizing healthcare delivery.

Market Snapshot: Positron Emission Tomography

The Positron Emission Tomography market advanced from USD 2.74 billion in 2024 to USD 2.92 billion in 2025, sustaining a CAGR of 6.60% and poised to reach USD 4.57 billion by 2032. This robust expansion reflects consistent investment in high-resolution imaging hardware, advanced digital PET technologies, and the broadening adoption of specialized radiotracers. Growing demand across oncology, neurology, and cardiology is matched by technology refinements and supportive reimbursement frameworks, driving adoption in established healthcare networks as well as emerging regions.

Scope & Segmentation

This report elucidates the opportunities and challenges within the global PET market by examining:

• Product Types:
  • Equipment: Dedicated PET Scanners, PET/CT Scanners
  • Radiotracers: Fluorodeoxyglucose (FDG)
• Applications:
  • Cardiology
  • Neurology
  • Oncology
• End Users:
  • Diagnostic Centers
  • Hospitals
  • Research Institutes
• Technologies:
  • Analog PET
  • Digital PET
  • Time-Of-Flight PET
• Geographies:
  • Americas: North America (United States, Canada, Mexico), Latin America (Brazil, Argentina, Chile, Colombia, Peru)
  • Europe, Middle East & Africa: Europe (United Kingdom, Germany, France, Russia, Italy, Spain, Netherlands, Sweden, Poland, Switzerland), Middle East (UAE, Saudi Arabia, Qatar, Turkey, Israel), Africa (South Africa, Nigeria, Egypt, Kenya)
  • Asia-Pacific: China, India, Japan, Australia, South Korea, Indonesia, Thailand, Malaysia, Singapore, Taiwan
• Key Companies:
  • GE HealthCare Technologies Inc., Siemens Healthineers AG, Koninklijke Philips N.V., Canon Medical Systems Corporation, United Imaging Healthcare Co., Ltd., Shimadzu Corporation, Bruker Corporation, Spectrum Dynamics Medical Ltd., Mediso Ltd, Sofie Biosciences, Inc.

Key Takeaways: Strategic Insights for Decision-Makers

• Digital PET and time-of-flight advancements are raising diagnostic precision, supporting early disease detection and personalized treatment strategies across major clinical specialties.
• Broader radiotracer pipelines are facilitating exploration of new biological markers, particularly in oncology and neurology, further diversifying potential indications for PET imaging.
• Shifting supply chain dynamics, including recent tariffs and regional sourcing adjustments, are prompting manufacturers and providers to pursue greater resilience and operational flexibility.
• Healthcare institutions are adopting comprehensive operational models—combining rapid scan throughput, multi-modality integration, and advanced analytics—to maximize clinical and economic outcomes.
• Collaborations among industry leaders and research institutes accelerate tracer innovation, streamline regulatory compliance, and support broader PET market penetration.

Tariff Impact: Navigating New Trade Realities

The 2025 implementation of new United States tariffs has introduced added complexity to the PET supply chain. Increased duties on detector modules, scintillation crystals, and other critical components are impacting manufacturing costs and radiotracer availability. In response, stakeholders are exploring nearshoring, leveraging free trade zones, and redefining supplier relationships to manage expense volatility and ensure timely access to essential technologies.

Methodology & Data Sources

This analysis synthesizes peer-reviewed literature, industry white papers, and regulatory filings with primary data from expert interviews and site-level utilization figures. Rigorous cross-validation with historical and regional trends underpins the credibility of market estimates and scenario analyses.

Why This Report Matters for PET Stakeholders

• Enables leadership teams to anticipate shifts in clinical demand, optimize PET investments, and align product strategies with evolving technology standards.
• Informs sourcing, partnerships, and operational planning in the face of new tariff regimes and increasingly complex supply chains.
• Equips healthcare providers with the strategic insights needed to maximize PET's clinical impact amid rising expectations for precision medicine.

Conclusion

By providing a comprehensive, actionable view of the Positron Emission Tomography market landscape, this report empowers leaders to navigate change and capture emerging opportunities. Strategic adoption of innovation and operational best practices will ensure sustained value and improved patient outcomes in the era ahead.

Additional Product Information:

• Purchase of this report includes 1 year online access with quarterly updates.
• This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.